London
· Delayed Price · Currency is GBP · Price in GBXAllergy Therapeutics Company Description
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders.
The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products.
Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus.
It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine.
The company operates in Germany, Austria, Netherlands, Switzerland, Italy, Spain, and internationally, as well as the United Kingdom.
Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
| Country | United Kingdom |
| Founded | 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 612 |
| CEO | Manuel Llobet |
Contact Details
Address: Dominion Way Worthing, BN14 8SA United Kingdom | |
| Phone | 44 1903 844 700 |
| Website | allergytherapeutics.com |
Stock Details
| Ticker Symbol | AGY |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | July - June |
| Reporting Currency | GBP |
| ISIN Number | GB00B02LCQ05 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Manuel Llobet | Chief Executive Officer |
| Shaun Furlong | Chief Financial Officer |